Guerbet has signed an exclusive agreement with icometrix for the distribution in France, Italy and Brazil of icobrain, their Saas (software as a service) artificial intelligence (AI) based medical imaging solution. According to a press release, icobrain is designed to help radiologists and neurologists diagnose and monitor patients with neurological disorders. The AI software extracts clinically meaningful information from brain CT or MRIs scans of patients with multiple sclerosis, dementia or brain injury. Icobrain can, therefore, be used to automate the currently manual process of identifying, marking and quantifying volumes of brain structures identified.
Icobrain has obtained marketing authorisations in numerous countries, including the USA, Europe, Canada, Brazil, Australia, Japan and India and is already used in more than 100 hospitals and imaging centres across the world, as well as in clinical studies from major global pharmaceutical companies. Icometrix, the press release says, is the world leader in software solutions to obtain clinically meaningful data from brain MRI and CT scans for patients with multiple sclerosis, traumatic brain injury, epilepsy, Alzheimer’s disease, stroke, etc.
Wim Van Hecke, CEO of icometrix, says: “There is a strong medical need to help radiologists, neurologists and patients with neurological disorders. This collaboration with Guerbet will allow us to serve hospitals in France, Italy and Brazil with the best support. Guerbet has many years of expertise in the radiology market and has a great reputation. We’re very much looking forward to this strategic partnership.”
The press release reports that Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. François Nicolas, chief digital officer for Guerbet, notes: “This agreement will allow more patients with neurological disorders to benefit from the icobrain AI technology. It will also allow Guerbet to expand its portfolio of augmented intelligence solutions beyond oncology, with the same aim of helping radiologists diagnose better and faster than ever before.”